NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

uniQure N.V. (QURE) Stock Analysis

uniQure N.V. (QURE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

QURE

$44.50

−$0.36 (−0.80%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QURE with… →

QURE Key Statistics

As of Sep 4, 2026
Trading
Open
$44.91
Previous Close
$44.86
Day's Range
43.90–45.16
52-Week Range
8.73–71.50
Volume
991.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.94
Valuation
Market Cap
$3.09B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
165.32
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.06
Financials (FY)
Revenue (FY)
$16.10M−40.64%
Net Income (FY)
−$198.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
69.37M
1-Year Return
+150.99%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
1.85M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

QURE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+85.96%
2025+35.50%
2024+160.86%
2023−70.14%
2022+9.31%
2021−42.60%
2020−49.58%
2019+148.65%
2018+47.12%
2017+249.82%
2016 (partial year)−32.12%

As of September 4, 2026.

QURE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.10M−$198.97M−1236.0%
2024$27.12M−$239.56M−883.4%
2023$15.84M−$308.48M−1947.1%
2022$106.48M−$126.79M−119.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.10M$14.41M−$187.83M−$198.97M−1236.0%
2024$27.12M$8.79M−$182.18M−$239.56M−883.4%
2023$15.84M$2.22M−$282.49M−$308.48M−1947.1%
2022$106.48M$103.14M−$144.25M−$126.79M−119.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QURE Valuation vs Biotechnology Median

Median of 656 stocks
MetricQUREBiotechnology medianvs median
P/S ratio165.3215.2610.8x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

uniQure N.V. (QURE) is capitalised at $3.09B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 221 employees.

The 52-week range on file runs from $8.73 to $71.50. The most recent close on file for QURE is $44.50, dated September 4, 2026. That is −$0.36 (−0.80%) against the previous close. The latest close sits 409.74% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $16.10M. That is −40.64% against the prior fiscal year, when revenue was $27.12M. The same year closed with a net loss of $198.97M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −4.06.

Across the 4 fiscal years on file, revenue moves from $106.48M in 2022 to $16.10M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 165.32 times revenue. On price-to-sales that is 10.8 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +150.99%. Measured over 10 years, that is +19.18% a year compounded. The reported beta is 0.94. Annualized volatility over the trailing 10 years is 122.23%.

Growth & Income

The record shows no dividend for QURE.

2026 is still running; the price is +85.96% year to date. The strongest complete calendar year on file is 2017 at +249.82%; the weakest is 2023 at −70.14%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

uniQure N.V. (QURE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
uniQure N.V. QURE $3.09B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. uniQure N.V. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Visit website →